Improving Outcomes for Adolescent/Young Adult and Adult Patients with ALL: Evaluating the Impact of Immunotherapy
December 12, 2022
December 12, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Catalyst Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare .
This activity is supported by educational funding provided by Amgen.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
The activity is intended primarily for hematology/oncology and medical oncology physicians and advanced practitioners caring for adult and AYA patients. Pediatric hematology/oncology and oncology clinicians who care for AYA patients may also find this material useful.
On-demand Oncology Expert Exchange: Clinical Case Challenge activity (Virtual Video Roundtable with Clinical Cases) with compelling reinforcing features. This initiative aims to close knowledge and competence gaps that result from the evolving clinical landscape to help HCPs enact appropriate treatment decision-making strategies for adult and AYA patients with ALL.
Upon completion of this activity, participants should be better able to:
- Recognize the significance of MRD monitoring in risk stratification, prognosis, and treatment selection in ALL
- Review strategies to assess and interpret MRD during and after ALL treatment
- Assess the clinical utility of immunotherapy agents in adult/AYA patients with MRD-positive or R/R ALL
- Evaluate recent data on immunotherapy as part of chemotherapy free first-line treatment paradigms for ALL
- Apply strategies to optimize treatment selections and management in adult/AYA ALL patients using clinical scenarios
Elias Jabbour, MD (Chairperson)
Professor of Medicine
Section Chief – ALL
Department of Leukemia
MD Anderson Cancer Center
University of Texas
Elias Jabbour, MD, joined the MD Anderson Cancer Center faculty in 2007 and is currently a professor of medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of other treatments. These include (1) the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD)-ofatumumab regimen for acute lymphoblastic leukemia (ALL); (2) clofarabine for myeloid malignancies; (3) hypomethylating agents for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); (4) tyrosine kinase therapy for chronic myeloid leukemia (CML); and (5) triple therapy for AML. This research has also provided insight into the biology of leukemias. Dr. Jabbour has extensively addressed resistance to tyrosine kinase inhibitors and analyzed the outcome of these patients. His team has identified different mechanisms of resistance and described the clinical significance in establishing new milestones and leading to personalized therapy, with tremendous consequences at the scientific and financial levels. Dr. Jabbour was also actively associated with frontline studies of nilotinib and dasatinib, which resulted in the US Food and Drug Administration approval of these agents for frontline CML therapy in 2010. In addition, his team has recently addressed genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world that randomized such patients to either 5-azacitidine or decitabine. Identifying patients who are at risk and applying earlier intervention may significantly improve their prognosis. He is leading efforts to test triple therapy in AML (nucleoside analogues + anthracyclines + cytarabine). The interim results from this randomized trial show a significant improvement in outcome in patients who receive the nucleoside analogue, clofarabine and may change the standard of care for the management of patients with AML. Furthermore, he is currently investigating the benefit of adding humanized monoclonal antibodies to the treatment of patients with ALL (HCVAD-ofatumumab) and collaborating in the development of monoclonal antibody studies in adult ALL. Finally, Dr. Jabbour has authored or co-authored hundreds of peer-reviewed medical publications and has served on editorial boards of several scientific journals.
Aaron C. Logan, MD, PhD
Associate Professor (Hematology/BMT)
University of California, San Francisco
San Francisco, CA
Aaron Logan, MD, PhD, is an associate professor of clinical medicine at the University of California, San Francisco (UCSF) in the Division of Hematology and Blood and Marrow Transplantation. His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia, and hemophagocytic lymphohistiocytosis. Dr. Logan is a specialist in non-transplant, transplant, and cellular therapies. He also runs a research laboratory and is Director of the Hematologic Malignancies Tissue Bank at UCSF. His research interests focus on the application of next-generation sequencing of immunoreceptor genes to quantify measurable residual disease (aka, minimal residual disease) in acute lymphoblastic leukemia, to quantify B- and T-cell immune reconstitution after allogeneic hematopoietic cell transplantation, and to quantify and track malignancy-, pathogen-, and autoantigen-targeted immune responses following transplantation or immunotherapy.
Hagop M. Kantarjian, MD
Professor and Chairman, Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
MD Anderson Cancer Center, University of Texas
Hagop M. Kantarjian, MD, is a professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. Also, he is the Samsung Distinguished Leukemia Chair in Cancer Medicine and a Special Fellow on Healthcare Policies at the Rice University Baker Institute in Houston, Texas, and advocates for healthcare issues pertinent to patients with cancer and leukemia.
Dr. Kantarjian’s research focuses on translational clinical developmental therapeutics in leukemia. In the past 3 decades, he has made several contributions that improved the prognosis and survival of patients with chronic myeloid leukemia (tyrosine kinase inhibitors such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, which improved the 10-year survival from 20%-90%) and acute lymphocytic leukemia (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen and its derivatives; antibodies including blinatumomab and inotuzumab), as well as discovered decitabine for the treatment of myelodysplastic syndrome and clofarabine for the treatment of leukemias, among others. His research and collaborations were the basis for the US Food and Drug Administration approvals of several drugs in leukemia.
Dr. Kantarjian has received several prestigious honours and awards, including the 37th Jeffrey A. Gottlieb Memorial Award, the John Mendelsohn Lifetime Scientific Achievement Award, the American Society of Clinical Oncology Joseph H. Burchenal Memorial Award, the Charles A. LeMaistre, MD Outstanding Achievement Award in Cancer, and the America’s Top Doctors Castle Connolly Medical award. He was also selected the top Castle Connolly National Physician of the Year Award for Lifetime Achievement. Dr. Kantarjian has authored more than 2000 peer-reviewed publications.
Physician Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credits™ awarded
Physician Credit Designation
Credit provided by AKH Inc., Advancing Knowledge in Healthcare.
Disclosures of Conflicts of Interest
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Elias Jabbour, MD (Chairperson), has disclosed no financial relationships.
- Aaron C. Logan, MD, PhD
- Researcher: Autolus, Kite, Talaris
Hagop M. Kantarjian, MD, has disclosed no financial relationships.
Jessica F Marshall, PhD, Director, Medical and Scientific Services, has disclosed no financial relationships
Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations, has disclosed no financial relationships.
Michele Bielarski, RN, Nurse Reviewer, has disclosed no financial relationships.
Trish Brignoni, AKH Director of Operations, has disclosed no financial relationships.
AKH and Catalyst Medical Education, LLC Planners and Reviewers, have disclosed no financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
If you have questions about this activity, please contact AKH Inc. at [email protected].